Long-term follow-up of people with chronic hepatitis B after AHB-137 injection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, open-label, multicenter long-term follow-up of people with chronic hepatitis B who previously received AHB-137 and achieved a complete or partial response without rescue medication. Participants who maintained response through the parent study End of Study visit will be followed for durability of virologic response with periodic visits and viral monitoring. The study is observational with no additional investigational interventions and excludes those who have enrolled in other interventional trials or who have conditions that contraindicate participation. Visits will be conducted at AusperBio investigational sites in Guangzhou and Changchun, China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Capable of giving informed consent.
* Participants who have previously received at least one dose of AHB-137 and achieved the complete of partial response in the parent study without rescue medication and who maintained response until the End of Study (EoS) visit in their parent study.

Exclusion Criteria:

* Participants who have/or are currently participating in another interventional clinical study since completing their treatment with AHB-137.
* Suspected for cancer at screening or any condition required hospitalization during this study , or any condition which, in the opinion of the investigator or Medical Monitor, contraindicates their participation in this study.

Where it's running

• AusperBio Investigational Site
  Chongqing, Chongqing Municipality, China Recruiting
• AusperBio Investigational Site
  Fuzhou, Fujian, China Recruiting
• AusperBio Investigational Site
  Guangzhou, Guangdong, China Recruiting
• AusperBio Investigational Site
  Guangzhou, Guangdong, China Recruiting
• AusperBio Investigational Site
  Changhou, Jiangsu, China Recruiting
• AusperBio Investigational Site
  Zhenjiang, Jiangsu, China Recruiting

Study contacts

• Principal investigator: Jinlin Hou — Nanfang Hospital, Southern Medical University
• Study coordinator: Lu
• Email: clinicaltrial@ausperbio.com
• Phone: 0571-86959519

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Impact of functional cure on patient-reported outcomes in chronic hepatitis B

  This study tests whether people with chronic hepatitis B who achieve a functional cure have better patient-reported outcomes compared to those not cured, relapse, or healthy controls.

  Recruiting Third Affiliated Hospital, Sun Yat-Sen University · Guangzhou · NCT07855029

• Sequential combination therapy for functional cure of chronic hepatitis B

  This trial tests a new two-drug approach to see if adding immunotherapy to ongoing HBV treatment can lead to loss of hepatitis B surface antigen in adults with chronic hepatitis B.

  Recruiting Phase 2 The Second Affiliated Hospital of Chongqing Medical University · Chongqing, Chongqing Municipality · NCT07852091

• Combination therapy for functional cure in chronic hepatitis B

  This phase 2 trial tests whether a sequence of anti-PD-1/PD-L1 antibodies with pegylated interferon and nucleos(t)ide analogues can achieve functional cure (HBsAg loss) in adults with chronic hepatitis B.

  Recruiting Phase 2 The Second Affiliated Hospital of Chongqing Medical University · Chongqing, Chongqing Municipality · NCT07845058

• GST-HG131/GST-HG141 tablets vs placebo in chronic hepatitis B

  A phase IIa trial tests GST-HG131 and GST-HG141 tablets against placebo to see if they are safe and help people with chronic hepatitis B.

  Recruiting Phase 2 Fujian Akeylink Biotechnology Co., Ltd. · Beijing · NCT07709520

• AHB-137 injection in people with chronic hepatitis B

  This study tests AHB-137 vs placebo in adults with chronic hepatitis B who have not yet received antiviral treatment.

  Recruiting at 34 sites Phase 2 Ausper Biopharma Co., Ltd. · Beijing, Beijing Municipality and 33 other locations · NCT07635186

• AHB-137 injection pharmacokinetics and safety in people with mild to moderate liver dysfunction and normal liver function

  This study tests how AHB-137 behaves in the body and its safety in adults with chronic hepatitis B who have mild to moderate liver problems or normal liver function.

  Recruiting Phase 1 Ausper Biopharma Co., Ltd. · Chongqing, Chongqing Municipality and 4 other locations · NCT07600788

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.